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Abstract 
Aims 
Inverse associations between vitamin D status and risk of type 2 diabetes observed in 
epidemiological studies could be biased by confounding and reverse causality. We 
investigated the prospective association between vitamin D status and type 2 diabetes and the 
possible role of reverse causality. 
 
Methods  
We conducted a case-cohort study within the Melbourne Collaborative Cohort Study 
(MCCS), including a random sample of 628 participants who developed diabetes and a sex-
stratified random sample of the cohort (n=1,884). Concentration of 25-hydroxyvitamin D 
(25(OH)D) was measured using liquid chromatography-tandem mass spectrometry in 
samples collected at recruitment. Logistic regression was used to estimate odds ratios (ORs) 
and 95% confidence intervals (CIs) for the risk of type 2 diabetes for quartiles of 25(OH)D 
relative to the lowest quartile and per 25 nmol/L increase in 25(OH)D, adjusting for 
confounding variables.  
 
Results  
The ORs for the highest versus lowest 25(OH)D quartile and per 25 nmol/L increase in 
25(OH)D were 0.60 (95% CI: 0.44, 0.81) and 0.76 (95% CI: 0.63, 0.92; p=0.004), 
respectively. In participants who reported being in good/very good/excellent health 
approximately four years after recruitment, ORs for the highest versus lowest 25(OH)D 
quartile and per 25 nmol/L increase in 25(OH)D were 0.46 (95% CI: 0.29, 0.72) and 0.71 
(95% CI: 0.56, 0.89; p=0.003), respectively.  
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Conclusions  
In this sample of middle-aged Australians, vitamin D status was inversely associated with the 
risk of type 2 diabetes, and this association did not appear to be explained by reverse 
causality. 
 
 
Keywords: Vitamin D; 25-hydroxyvitamin D; Vitamin D deficiency; Type 2 diabetes 
mellitus 
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1 Introduction 
Globally the prevalence of type 2 diabetes is increasing and if current trends continue, more 
than 642 million people (10% of adults) will have diabetes by 2040 [1]. Well-established risk 
factors for type 2 diabetes include excess body weight (particularly abdominal adiposity), 
physical inactivity, poor diet, increasing age, family history of type 2 diabetes, ethnicity, and 
genetics [1]. Identifying other risk factors could inform strategies for prevention. 
 
Vitamin D has been linked to the pathogenesis of type 2 diabetes [2-7]. Several meta-
analyses of prospective studies have found an inverse association between vitamin D status, 
as assessed by circulating serum or plasma 25-hydroxyvitamin D (25(OH)D) concentrations, 
and risk of type 2 diabetes [8, 9]. However, these results have not been replicated in 
randomised controlled trials (RCTs) of vitamin D supplementation [10], and a recent 
umbrella review of the literature pertaining to vitamin D and multiple health outcomes 
concluded that there was only suggestive evidence of an association between vitamin D and 
type 2 diabetes [11]. Existing RCTs have been criticised for design limitations such as lack of 
statistical power and inclusion of vitamin D replete individuals [12, 13], while results from 
observational studies could be biased by confounding and reverse causality. Confounding is 
possible because vitamin D status is associated with several risk factors for diabetes (such as 
obesity, physical inactivity, age and ethnicity). Reverse causality would occur if study 
participants were in poor health at study entry due to undiagnosed diabetes, and this led to 
poor vitamin D status (for example via reduced sun exposure, dietary changes, or increased 
inflammation). Existing prospective cohort studies have not extensively explored the 
possibility of reverse causality, engendering uncertainty regarding any potential benefit of 
vitamin D for the prevention of type 2 diabetes. 
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We investigated the association between vitamin D status and the risk of type 2 diabetes in a 
large population-based prospective cohort study and examined whether this association is 
likely to be explained by reverse causality. 
 
2 Subjects, Materials and Methods 
A case-cohort study to investigate vitamin D status and the risk of cancer, type 2 diabetes and 
mortality was conducted within the Melbourne Collaborative Cohort Study (MCCS). The 
MCCS is a prospective cohort study of 41,514 participants (24,469 women and 17,045 men) 
living in the Melbourne metropolitan area who were predominantly aged between 40 and 69 
years at study recruitment (1990-1994). Southern European migrants were deliberately 
recruited (approximately 25% of the cohort) to extend the range of dietary and lifestyle 
exposures. Details of the MCCS have been published [14]. Briefly, at baseline (wave 1) 
extensive demographic, lifestyle and dietary data were collected, and anthropometric 
measurements were performed. Participants were also asked whether they had ever been 
diagnosed with diabetes mellitus. Blood samples were collected, from which plasma glucose 
concentrations (67% fasting) were measured using Kodak Ektachem DT60 desktop analysers 
(Rochester, NY). From one year into study recruitment (for approximately 75% of 
participants), whole blood was spotted onto Guthrie cards, which were air dried and stored in 
dark conditions. 
 
Approximately four years after baseline (wave 2), participants were mailed a self-
administered questionnaire which asked about non-fatal and non-cancer health events, 
including diabetes. For self-reported incident cases of diabetes, 76% were confirmed by their 
GP as having type 2 diabetes [15]. Participants were also asked: “In general, would you say 
your health is: excellent, very good, good, fair, or poor?”. A third wave of data collection was 
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conducted between 2003 and 2007, when participants attended a clinic where further 
questionnaires were completed, anthropometric measurements, medication use (including 
insulin and oral hypoglycemics), and several disease endpoints were recorded, and another 
blood sample was collected. Plasma glucose concentrations were measured using a 
glucometer. Self-reported diabetes status and year of diagnosis were also recorded. 
 
The Cancer Council Victoria’s Human Research Ethics Committee approved the study 
protocol and participants gave written consent to participate.  
 
2.1 Participants 
Eligibility for the case-cohort study was restricted to the 29,206 participants who had no 
cancer diagnosis before baseline and for whom dried blood spots were available from 
baseline blood samples. For the diabetes component, we excluded 132 people with pre-
existing diabetes or unknown diabetes status at baseline, where diabetes status was 
determined from self-report or plasma glucose concentrations (see Table 1), leaving 29,074 
eligible. 
 
The diabetes study included a random sample of participants who developed diabetes 
between baseline and wave 3, and a sex-stratified random sample of all eligible participants 
(‘subcohort’). Participants for whom 25(OH)D measurements were not performed, with 
missing data for any confounding variable, or with extreme total energy intakes (<1
st
 and 
>99
th
 sex-specific percentiles) were excluded. Participants with missing data on diabetes 
status were excluded from analyses because their case status was unknown. 
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2.2 Assessment of vitamin D status 
Concentrations of 25(OH)D2 and 25(OH)D3 from baseline dried blood spot samples were 
measured using liquid chromatography-tandem mass spectrometry and summed to give total 
25(OH)D [16]. Samples were processed in random order and laboratory analysts were blind 
to outcome status of participants. Results are presented for total 25(OH)D concentrations. 
Analyses were also conducted using 25(OH)D3 but there was no material difference in 
results, as few participants had any circulating 25(OH)D2, which also precluded separate 
analysis of 25(OH)D2. To remove batch effects, a mixed-effects linear regression model with 
a random effect for batch was fitted for 25(OH)D levels of subcohort participants, then for all 
participants, the predicted batch-specific deviations from the overall mean were subtracted 
from the observed values. Concentrations of 25(OH)D exhibited sinusoidal seasonal 
variation, which was removed using trigonometric regression [17]. Concentrations of 
25(OH)D are reported as plasma equivalents, obtained using a previously developed 
calibration equation [18]. Participants were divided into sex-specific quartiles based on the 
distribution of batch- and season-adjusted plasma 25(OH)D for the subcohort. 
 
2.3 Ascertainment of diabetes cases 
Diabetes status was assessed at baseline, wave 2 and wave 3 using the criteria shown in Table 
1. On each occasion, participants who satisfied any of the criteria were classified as having 
diabetes, while those with incomplete information were classified as having missing diabetes 
status. The World Health Organization diagnostic criteria for plasma glucose concentrations 
indicative of diabetes were used [19]. No distinction between type 1 and type 2 diabetes was 
made, however, all incident cases were assumed to be type 2 because this is most likely after 
the age of 40 years [15, 20]. Classification of diabetes status at wave 3 used the same criteria 
as at baseline, except that where diabetes status was missing, participants using any diabetes 
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medication were classified as a case, while those who did not report using any diabetes 
medications were considered not to have diabetes. A participant was classified as an incident 
case if they did not have diabetes at baseline and were identified as a case at either wave 2 or 
wave 3. 
 
2.4 Confounders 
The following confounding variables measured at baseline were included in analyses based 
on a priori knowledge and use of a causal diagram: sex, age (six categories: <45, 45–49, 50–
54, 55–59, 60–64, and ≥65 years), country of birth (Australia/New Zealand/Northern Europe 
or Southern Europe), an area-based measure of socio-economic status (Socio-Economic 
Indexes for Areas (SEIFA); quintiles from most disadvantaged to least disadvantaged), 
highest education level attained (primary school, some secondary school, secondary school, 
and tertiary qualification), alcohol consumption (five categories: never, former, and sex-
specific tertiles of current intake), smoking status (never, former, current), physical activity 
(four categories reflecting the frequency and intensity of recreational activity in the past 6 
months), waist circumference (sex-specific quartiles, cm), Mediterranean diet score (three 
categories, with the highest indicating high adherence to a Mediterranean dietary pattern), 
margarine intake (quartiles, times/week), total energy intake (sex-specific quartiles, kJ/day), 
history of hypertension at baseline, and history of cardiovascular disease (CVD; includes 
history of angina, myocardial infarction, or stroke) at baseline. Margarine intake was 
included because margarine is fortified with vitamin D in Australia and it was associated with 
circulating 25(OH)D concentration in this cohort (data not shown), and because 
polyunsaturated or monounsaturated fats (which are present in margarine) have been reported 
to be associated with the risk of type 2 diabetes [21, 22]. 
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2.5 Statistical analyses 
Statistical analyses were performed using Stata version 14.1 (StataCorp, College Station, 
Texas, USA).  
 
In light of the unconventional design of this study, with ascertainment of case status at two 
time points, there was no established strategy to use for analysing the data. Two strategies 
were explored, with no material difference in their results.  
 
All results presented are from an analysis strategy that resembled a nested case-control study 
with density sampling. Three controls per case were selected (without replacement) at the 
same time as cases were identified and matched on sex. The flow diagram of participants 
included in the main analyses and their case status at each wave is shown in Figure 1. There 
were 83 women and 77 men (total 160) with diabetes at wave 2. A random sample of 249 
female and 231 male controls (total 480) was selected from the 2,391 subcohort participants 
who completed the wave 2 questionnaire and did not have diabetes at wave 2 (regardless of 
whether they later developed diabetes). There were 231 women and 237 men (total 468) with 
incident diabetes identified at wave 3 (i.e. who were not cases at wave 2). A sample of 693 
female and 711 male controls (total 1,404) was randomly selected from the 1,491 subcohort 
participants who were not selected as controls at wave 2, attended the wave 3 clinic, and had 
not developed diabetes before wave 3.  
 
The alternative analysis strategy was based on a nested case-control study with selection of 
controls at the end of follow-up (sometimes referred to as cumulative sampling). Cases were 
all people with diabetes (randomly selected cases plus subcohort cases) regardless of when 
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they were identified as having diabetes (at wave 2 or wave 3). Controls were all members of 
the subcohort who attended the wave 3 clinic, and had not developed diabetes before wave 3 
(n=1,827). Results from this approach are presented in the Supplementary material. 
 
Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals 
(CIs) for the risk of diabetes for each quartile of 25(OH)D relative to the lowest quartile, with 
adjustment for the confounders listed above. Test for trend across categories was performed 
by including categorical 25(OH)D as a linear term in the model. The OR per 25 nmol/L 
increase in 25(OH)D was estimated by using the continuous form of this variable. Potential 
non-linearity of the dose-response relationship was explored by fitting a restricted cubic 
spline model with four knots at fixed and equally-spaced percentiles (5%, 35%, 65%, 95%) 
of 25(OH)D. 
 
2.5.1 Interaction by time since baseline 
An interaction was fitted between 25(OH)D and time since baseline, where time=0 for wave 
2 cases and controls, and time=1 for wave 3 cases and controls. This analysis was designed to 
assess whether the association differed by time since baseline (using two time points as it was 
not possible to assess time continuously).  
 
2.5.2 Effect modification by sex and baseline disease status 
To explore possible effect modification by sex, an interaction was fitted between continuous 
25(OH)D and sex. Effect modification by baseline disease status was assessed by fitting 
interactions between continuous 25(OH)D and history of hypertension and history of CVD. 
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2.5.3 Sensitivity analysis 
To investigate potential reverse causality, a sensitivity analysis was performed restricted to 
the 2,281 participants who reported being in good, very good, or excellent health at wave 2 
and who did not have diabetes at wave 2. Of these, 139 women and 159 men (total 298) had 
diabetes at wave 3. A random sample of 417 female and 477 male controls (total 894) was 
selected from subcohort participants who did not have diabetes at wave 3. 
 
3 Results 
3.1 Participants 
Of the 3,408 participants selected for the diabetes case-cohort study, 25(OH)D measurements 
were not performed for 13 participants, confounder data was missing for 17 participants, and 
55 had extreme values for daily total energy intake. After exclusion of these participants, 
3,323 were eligible for analysis. In total, 628 people with diabetes were included in the 
analyses, of whom 109 were in the subcohort and 519 were non-subcohort cases. Controls for 
the nested density-sampled case-control study (for which results are presented) comprised 
480 subcohort participants who did not develop diabetes before wave 2 (eight of whom later 
developed diabetes), and a further 1,404 subcohort participants who were selected as controls 
at wave 3, as shown in Figure 1. Characteristics of diabetes cases and these subcohort 
controls are shown in Table 2. 
 
3.2 Main results 
The OR for the highest compared with the lowest 25(OH)D quartile was 0.60 (95% CI: 0.44, 
0.81) and the OR per 25 nmol/L increase in 25(OH)D was 0.76 (95% CI: 0.63, 0.92; 
p=0.004). Results were similar for 25(OH)D3 (data not shown). There was evidence that the 
spline model fitted better than a linear trend (p=0.003), with a sharp reduction in risk as 
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25(OH)D increased from 40 to 60 nmol/L, followed by a plateau at higher 25(OH)D 
concentrations (Figure 2). Results from the alternative analysis strategy were almost identical 
(Supplementary Table 1). 
 
3.2.1 Interaction by time since baseline 
The average time between baseline (wave 1) and wave 2 was 4.0 (SD, 0.4) years (maximum 
6.8 years) and the average time between baseline and wave 3 was 11.4 (SD, 1.2) years 
(maximum follow-up time=14.6 years). The ORs were similar for the two strata defined by 
follow-up period (Table 3). For the quartile analysis, p for time interaction=0.69 and for the 
continuous analysis, p for time interaction=0.42. 
 
3.2.2 Effect modification by sex and baseline disease status 
There was no evidence that the association varied by sex (p for interaction=0.49). There was 
no evidence of interaction between vitamin D status and history of hypertension at baseline (p 
for interaction=0.35), based on 505 participants (213 cases) with a history pf hypertension. 
Similarly, there was no evidence of interaction between vitamin D status and history of CVD 
at baseline (p for interaction=0.79), based on 145 participants (54 cases) with a history of 
CVD. 
 
3.3 Sensitivity analysis: association between vitamin D status and diabetes for people 
in good to excellent health at wave 2 
The sensitivity analysis included 298 diabetes cases and 894 controls (total 1,192 
participants). The association for these participants was slightly stronger than for all 
participants. The OR for the highest compared with the lowest 25(OH)D quartile was 0.46; 
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95% CI: 0.29, 0.72; ptrend<0.001) and the OR per 25 nmol/L increase in 25(OH)D was 0.71 
(95% CI: 0.56, 0.89; p=0.003).  
 
4 Discussion 
Vitamin D status was inversely associated with the incidence of type 2 diabetes over 11 years 
of follow-up. Each 25 nmol/L increment in 25(OH)D was associated with an approximately 
24% lower risk of type 2 diabetes after controlling for well-known risk factors, with some 
evidence that the dose-response curve plateaued at higher concentrations. The association 
was slightly stronger for participants who reported being in good to excellent health 
approximately 4 years after baseline; these participants had a 29% lower risk of type 2 
diabetes per 25 nmol/L increment in 25(OH)D during an interval approximately 4 to 11 years 
after baseline. 
 
Strengths of this study include the prospective design, long follow-up, large number of cases, 
extensive data on potential confounders, and generalisability based on a broad age range and 
community-based recruitment. A major strength was the availability of data on general health 
status several years after blood samples were collected, which facilitated assessment of 
reverse causality. Limitations included the different methods used to assess diabetes status at 
each wave of follow-up, and that participants were not specifically asked whether they had 
type 1 or type 2 diabetes. Nevertheless, it is unlikely that participants developed type 1 
diabetes during follow-up because this is usually diagnosed before the age of 40 years [20]. 
Few participants in this study had circulating 25(OH)D2 which precluded assessment of the 
association between 25(OH)D2 and diabetes. Reported 25(OH)D concentrations should be 
interpreted cautiously as these were plasma-equivalent concentrations estimated from dried 
blood spots and adjusted for batch and season [18]. A potential source of bias was selection 
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bias due to people not participating in wave 2 or wave 3. Selection bias would occur if 
participation was a common “effect” of 25(OH)D concentrations and the outcome. However, 
for the subcohort, inclusion in the analyses was not strongly associated with 25(OH)D 
concentrations (data not shown), suggesting that selection bias is unlikely to explain the 
observed association between 25(OH)D and risk of diabetes. The MCCS only included 
participants of European descent, thus the results cannot necessarily be extrapolated to other 
ethnicities. Because diabetes status was assessed at two different time points, and there are no 
definitive analysis methods for this unconventional case-cohort study design, two separate 
analysis strategies were employed, and there was no material difference in results between 
them. It is therefore unlikely that the results were biased by the analysis strategy. While 
adjustments were made for known confounders, the possibility of residual confounding 
cannot be ruled out. Nevertheless, analyses from the National Health and Nutrition 
Examination Surveys (NHANES) showing consistent inverse associations between 25(OH)D 
concentrations and diabetes risk among non-Hispanic whites and Mexican-Americans, but 
not among non-Hispanic blacks [23], suggest that the association between 25(OH)D and 
diabetes is unlikely to be due to inadequate control for confounding, which might be expected 
to work the same way across the ethnic groups. 
 
Despite consistent evidence from observational studies of an inverse association between 
25(OH)D concentrations and incident type 2 diabetes [8, 9], there is no evidence from RCTs 
to support a causal association [10]. A possible explanation for the null results from RCTs is 
that vitamin D sufficiency might need to be sustained over long periods to have any benefit. 
It is also possible that vitamin D sufficiency might need to be maintained throughout the 
entire lifetime, and supplementation may not be able to reverse disease processes once they 
are initiated [13, 24]. The results from this study, in which the association did not markedly 
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change over time, and was stronger for participants in good to excellent health some years 
after blood sampling, support the notion that adequate vitamin D is required to reduce the risk 
of diseases that progress over a period of several years, and that vitamin D adequacy may be 
required long before the disease process is established.  
 
A Mendelian randomisation study of common genetic variants related to 25(OH)D synthesis 
and metabolism found that 7-dehydrocholesterol reductase (DHCR7) variants associated with 
low plasma 25(OH)D concentration were associated with an increased risk of diabetes (OR 
for a genetically determined 20 nmol/L lower 25(OH)D=1.51; 95% CI: 0.98, 2.33; ptrend=0.04 
for type 2 diabetes and 1.54; 95% CI: 1.03, 2.30 for any diabetes) [25]. The same study 
showed no significant associations between CYP2R1 variants or allele scores and the risk of 
diabetes (OR for a genetically determined 20 nmol/L lower 25(OH)D=1.02; 95% CI: 0.75, 
1.37; ptrend=0.84 for type 2 diabetes and 1.01; 95% CI: 0.76, 1.35 for any diabetes) [25]. 
Another Mendelian randomisation study did not find a statistically significant relationship 
between genetically low 25(OH)D (using four genetic variants) and the risk of type 2 diabetes 
(OR per 25 nmol/L lower 25(OH)D=0.93; 95% CI: 0.77, 1.13; p=0.46); this association was 
in the opposite direction to that reported in the aforementioned Mendelian randomisation 
study, and the authors concluded that there was inadequate evidence to support a causal 
relationship [26]. Taken together, these findings suggest that reverse causality might explain 
the results from observational studies. 
 
The possibility of reverse causality has been a limitation of existing observational studies 
investigating the association between vitamin D status and disease. This is of particular 
concern for an outcome such as diabetes, for which people can remain asymptomatic and 
undiagnosed for years [1]. It is possible that lifestyle changes (e.g. in diet and outdoor 
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activity) or suboptimal health prior to diagnosis, for example increased inflammation [27], or 
hyperglycaemia causing tissue damage in undiagnosed diabetes, could provoke a reduction in 
25(OH)D concentrations. If the association was due to reverse causality then a much stronger 
association would be expected to be observed in the first few years of follow-up. In the 
MCCS, the association at wave 2 (approximately 4 years after baseline) was similar to the 
association at wave 3 (approximately 11 years after baseline). The persistence of the 
association over time suggests that reverse causality is an unlikely explanation for the 
association observed in this study. However, due to the limited number of cases at wave 2 
(n=160), any potential interaction with time could not be explored in depth. The sensitivity 
analysis restricted to participants who reported being in good to excellent health permitted a 
more thorough exploration of whether reverse causality could explain the observed 
association. The association was slightly stronger for participants who were in good/very 
good/excellent health approximately 4 years after baseline. For these participants, the risk of 
diabetes was approximately 54% lower for those with the highest compared with the lowest 
25(OH)D concentrations. These findings imply that the association between vitamin D status 
and diabetes in this study is unlikely to be due to reverse causality. 
 
The Australian Diabetes, Obesity and Lifestyle (AusDiab) study reported that each 25 nmol/L 
increment in 25(OH)D was associated with a 24% lower risk of developing type 2 diabetes 
(OR = 0.76, 95% CI: 0.63, 0.92) [28]. The results of this small study (199 diabetes cases 
diagnosed during 5 years of follow-up) are consistent with our findings from the MCCS, 
providing strong evidence that vitamin D insufficiency is associated with an increased risk of 
type 2 diabetes among Australians.  
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Several reviews have outlined potential mechanisms for a role of vitamin D in the 
pathogenesis of type 2 diabetes [2-7]. Vitamin D might contribute to type 2 diabetes by 
influencing insulin secretion and sensitivity [4, 5, 29]. The function of pancreatic beta cells, 
which produce insulin, appears to be influenced by vitamin D. In particular, the active form 
of vitamin D3, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] is believed to be important for 
insulin synthesis and secretion [2-4, 29-31]. Pancreatic beta cells possess vitamin D receptors 
(VDRs) [32], and express the 1α-hydroxylase enzyme which converts 25(OH)D3 to the active 
form [1,25(OH)2D3] [33]. Vitamin D is also thought to influence insulin secretion via 
extracellular and intracellular calcium levels, which govern release of insulin from beta cells 
[2, 3, 29, 34]. Tissues involved in the development of type 2 diabetes, such as adipose tissue 
and skeletal muscle, have VDRs, and locally-produced 1,25(OH)2D3 in these tissues increases 
insulin sensitivity [7]. Vitamin D could also contribute to insulin sensitivity by regulating 
extracellular calcium, calcium influx, and intracellular calcium concentrations required for 
insulin-mediated functions such as glucose transport [2]. In addition, a vitamin D response 
element (VDRE) is present in the promoter region of the insulin receptor gene [35], and 
1,25(OH)2D3 activates expression of this gene [36]. Consistent with experimental studies, 
observational studies have found an inverse association between 25(OH)D concentrations and 
insulin resistance [28, 37-39]. Finally, vitamin D could also indirectly contribute to the 
pathogenesis of type 2 diabetes via regulation of inflammatory processes (such as production 
of cytokines) associated with insulin resistance and beta cell death [2, 7, 40]. 
 
Overall, a putative role of vitamin D in the aetiology of type 2 diabetes appears to be 
biologically plausible. In the MCCS, vitamin D status was inversely associated with the 
incidence of type 2 diabetes, and this association did not appear to be explained by reverse 
causality. Further long-term intervention studies in vitamin D deficient people at risk for 
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diabetes are required to confirm whether vitamin D is causally associated with type 2 
diabetes. 
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Table 1: Criteria for diabetes mellitus at baseline and each wave of follow-up. 
 
Time point Definition of diabetes mellitus 
Baseline/Wave 1 (1990 – 1994) Fasting plasma glucose ≥ 7.0 mmol/L, or 
Non-fasting plasma glucose ≥ 11.1 mmol/L, or 
Self-reported diabetes 
Wave 2 (1995 – 2002)  Self-reported diabetes 
Wave 3 (2003 – 2007) Fasting plasma glucose ≥ 7.0 mmol/L, or 
Non-fasting plasma glucose ≥ 11.1 mmol/L, or 
Self-reported diabetes, or 
Using diabetes medication 
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Table 2: Characteristics of diabetes cases and subcohort participants without diabetes. 
 Subcohort non-cases Diabetes cases 
N 1,884 628 
25(OH)D (nmol/L), median (IQR)  49.7 (23.4) 44.6 (22.6) 
Sex   
Female 942 (50.0) 314 (50.0) 
Male 942 (50.0) 314 (50.0) 
Age (years), median (IQR) 53.1 (14.7) 55.8 (13.3) 
Country of birth   
Australia/New Zealand/Northern Europe 1,649 (87.5) 457 (72.8) 
Southern Europe 235 (12.5) 171 (27.2) 
Socioeconomic disadvantage   
1st quintile (most disadvantage) 210 (11.1) 108 (17.2) 
2nd quintile 274 (14.5) 118 (18.8) 
3rd quintile 299 (15.9) 116 (18.5) 
4th quintile 453 (24.0) 132 (21.0) 
5th quintile (least disadvantage) 648 (34.4) 154 (24.5) 
Educational attainment   
Primary school or less 157 (8.3) 124 (19.7) 
Some secondary school 687 (36.5) 267 (42.5) 
Secondary school 452 (24.0) 126 (20.1) 
Tertiary qualification 588 (31.2) 111 (17.7) 
Alcohol intake (g/day)   
Never  401 (21.3) 194 (30.9) 
Former  70 (3.7) 34 (5.4) 
Current low 451 (23.9) 150 (23.9) 
Current medium 461 (24.5) 126 (20.1) 
Current high  501 (26.6) 124 (19.7) 
Smoking   
Never 1,085 (57.6) 351 (55.9) 
Former 632 (33.5) 205 (32.6) 
Current 167 (8.9) 72 (11.5) 
Physical activity   
None 356 (18.9) 173 (27.5) 
Low 370 (19.6) 126 (20.1) 
Moderate  618 (32.8) 219 (34.9) 
High  540 (28.7) 110 (17.5) 
Waist circumference (cm, quartiles)a   
1 526 (27.9) 24 (3.8) 
2 487 (25.8) 68 (10.8) 
3 499 (26.5) 157 (25.0) 
4 372 (19.7) 379 (60.4) 
Mediterranean diet score   
0 – 3 (low) 428 (22.7) 165 (26.3) 
4 – 6 (moderate) 1,191 (63.2) 395 (62.9) 
7 – 9 (high) 265 (14.1) 68 (10.8) 
Margarine intake (times/week, quartiles)   
0.0 – 0.4 354 (18.8) 118 (18.8) 
0.5 – 6.9 514 (27.3) 182 (29.0) 
7.0 – 17.4 445 (23.6) 140 (22.3) 
≥ 17.5 571 (30.3) 188 (29.9) 
Energy intake (kJ/day, quartiles)b   
1 422(22.4) 176 (28.0) 
2 503 (26.7) 155 (24.7) 
3 490 (26.0) 132 (21.0) 
4 469 (24.9) 165 (26.3) 
History of hypertension 292 (15.5) 213 (33.9) 
History of cardiovascular disease (angina, 
myocardial infarction or stroke) 
91 (4.8) 54 (8.6) 
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Unless otherwise specified, all values are reported as n (%) 
aQuartiles of waist circumference in cm: 
1, Females 52.7-70.5; Males 62.0-85.9 
2, Females 70.6-76.9; Males 86.0-91.9 
3, Females 77.0-85.4; Males 92.0-98.3 
4, Females 85.5-137.0; Males 98.4-131.0 
bQuartiles of total energy intake in kJ/day: 
1, Females 3,214-6,278; Males 3,755-7,369 
2, Females 6,279-8,006; Males 7,370-9,213 
3, Females 8,007-9,845; Males 9,214-11,476 
4, Females 9,846-18,831; Males 11,477-21,650 
 
  
27 
 
Table 3: Odds ratios (ORs) and 95% confidence intervals (CIs) for the risk of type 2 
diabetes by concentrations of 25(OH)D. 
 
  25(OH)D
a
 
  Median 
(IQR), 
nmol/L 
N Cases  OR
b 
(95% CI) ptrend 
Overall       
Quartiles Q1 31.4 (7.3) 623 200 1.00 (ref) <0.001 
 Q2 42.9 (10.4) 642 175 0.87 (0.65, 1.15)  
 Q3 53.0 (13.6) 626 135 0.70 (0.52, 0.94)  
 Q4 72.1 (19.4) 621 118 0.60 (0.44, 0.81)  
Per 25 nmol/L increase  48.3 (23.8) 2,512 628 0.76 (0.63, 0.92) 0.004 
Wave 2       
Quartiles Q1 30.8 (7.4) 161 51 1.00 (ref) 0.04 
 Q2 42.8 (11.6) 155 43 0.73 (0.42, 1.30)  
 Q3 53.0 (13.1) 159 38 0.78 (0.44, 1.38)  
 Q4 70.6 (20.5) 165 28 0.51 (0.28, 0.93)  
Per 25 nmol/L increase  49.5 (23.2) 640 160 0.68 (0.50, 0.93) 0.02 
Wave 3       
Quartiles Q1 31.7 (7.1) 462 149 1.00 (ref) 0.01 
 Q2 42.9 (9.9) 487 132 0.92 (0.66, 1.27)  
 Q3 52.8 (13.9) 467 97 0.68 (0.49, 0.96)  
 Q4 72.9 (18.9) 456 90 0.64 (0.45, 0.91)  
Per 25 nmol/L increase  48.1 (24.0) 1,872 468 0.79 (0.64, 0.97) 0.03 
CI = confidence interval; IQR = interquartile range; OR = odds ratio; Q = quartile; N = number of participants; 
ref = reference 
aPlasma equivalent concentrations adjusted for batch and seasonal effects. 
bAdjusted for sex, age, country of birth, socioeconomic status, education, alcohol, smoking, physical activity, 
waist circumference, Mediterranean diet score, margarine intake, total energy intake, history of hypertension at 
baseline, and history of cardiovascular disease at baseline. 
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Figure legends 
 
Figure 1: Flow diagram of participants included in the main analyses. 
Participants included in the main analyses are shown in shaded boxes. A random sample of 
480 participants was selected as wave 2 controls from the 2,391 subcohort participants 
without diabetes at wave 2. There were 1,491 subcohort participants who were not selected as 
wave 2 controls who attended wave 3, and did not have missing data on diabetes, and did not 
develop diabetes before wave 3. From these participants, a random sample of 1,404 
participants was selected as wave 3 controls. ‘Dead’ at wave 2 means the participant did not 
complete the questionnaire and died between baseline and 20 June 2002 (final date of wave 
2). ‘Dead’ at wave 3 means the participant did not attend wave 3 and died between wave 2 
and 16 June 2007 (final date of wave 3).  
 
 
 
 
Figure 2: Odds ratios for 25(OH)D concentration and the incidence of type 2 diabetes. 
Odds ratios (ORs) are shown by quartiles of 25(OH)D and from analysis of restricted cubic 
splines (dashed curve). 
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Baseline (wave 1) 
 
Wave 3 
Wave 2  
Eligible for analysis 
n = 3,323 
Diabetes 
n = 21 
Dead 
n = 60 
Diabetes 
n = 139 
Subcohort 
n = 2,804 
Non-subcohort diabetes cases 
n = 519 
Diabetes 
n = 8 
Diabetes 
n = 69 
No diabetes 
n = 1,340 
Missing data 
on diabetes 
n = 70 
Dead 
n = 98 
Diabetes 
n = 11 
Did not 
attend 
n = 334 
Dead 
n = 16 
Missing data 
on diabetes 
n = 6 
Did not 
attend 
n = 148 
Diabetes 
n = 56 
Diabetes 
n = 324 
No diabetes 
n = 151 
Controls 
n = 480 
Controls 
n = 1,404 
No diabetes 
n = 2,391 
Did not complete 
questionnaire 
n = 332 
No diabetes 
n = 324 
Did not complete 
questionnaire 
n = 56 
Exclusions: 
25(OH)D measurements not performed n = 13 
Missing confounder data n = 17 
Extreme daily energy intakes n = 55 
 
MCCS 
n = 41,514 
Eligible for case-cohort study 
n = 29,206 
Ineligible: 
Pre-baseline cancer diagnosis or  
no dried blood spot samples n = 12,308 
Participants selected 
n = 3,408 
Exclusions: 
Pre-baseline diabetes n = 128 
Unknown diabetes status at baseline n = 4 
 
  
